The Technical AnalystExchange: TSX Industry: Biotechnology
BELLUS Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.10% $19.48
America/New_York / 29 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 470.30 mill |
| EPS: | -0.960 |
| P/E: | -20.29 |
| Earnings Date: | Aug 07, 2023 |
| SharesOutstanding: | 126.81 mill |
| Avg Daily Volume: | 0.0694 mill |
| RATING 2023-06-29 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -20.29 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -20.29 | industry: PE -18.01 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 19.29 - 19.67 ( +/- 0.99%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.48 (-0.10% ) |
| Volume | 0.0287 mill |
| Avg. Vol. | 0.0694 mill |
| % of Avg. Vol | 41.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLU.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BLU.TO
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.